What Neurocrine Biosciences Inc does.

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.

Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc. In addition, we have a diversified portfolio of multiple compounds in mid- to late-phase development across our core therapeutic areas and an expanding early-phase pipeline that includes a range of modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.

We launched INGREZZA ® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of TD in May 2017 and for the treatment of chorea associated with Huntington's disease in August 2023 and launched CRENESSITY ® (crinecerfont) in the U.S. as a first-in-class FDA-approved treatment of CAH in December 2024.

Revenue and profit, by fiscal year.

More on NBIX.

• Neurocrine Biosciences Inc summary
• Neurocrine Biosciences Inc financial statements
• Neurocrine Biosciences Inc key metrics
• Neurocrine Biosciences Inc health scores and style box
• Neurocrine Biosciences Inc earnings
• Neurocrine Biosciences Inc dividends
• Neurocrine Biosciences Inc valuation
• Neurocrine Biosciences Inc ownership and insiders
• Neurocrine Biosciences Inc peers

Figures from Neurocrine Biosciences Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.